ACUR Forecast and Technical Stock Analysis

Buy candidate since 2019-07-19

Acura Pharmaceuticals gained 45.58% in the last trading day ( Friday, 19th Jul 2019 ), rising from $0.14 to $0.21 During day the stock fluctuated 37.42% from a day low at $0.15 to a day high of $0.21. The price has fallen in 7 of the last 10 days and is down by -23.42% for this period. Volume fell in the last day by -22 168 shares, and in total, 2 452 shares bought and sold for approximately $505.11. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.

Quick summary:

  • 30 day high of the ACUR stock price was $0.27 and low was $0.13.
  • 90 day high was $0.28 and low was $0.13.
  • 52 week high for the Acura Pharmaceuticals - $0.37 and low - $0.06.
Top Trending Stocks


Acura Pharmaceuticals lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -10.51% during the next 3 months and, with 90% probability hold a price between $0.11 and $0.24 at the end of this period.

Top Golden Star Stocks


Acura Pharmaceuticals holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $0.20 and $0.19. A break down below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Thursday July 18, 2019, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Relative Strength Index (RSI)

RSImin/max Values: [ 25 - 75 ]

RSI14 is 58 and the stock is currently not being overbought or oversold

* Stockinvest.us uses dynamical calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Support & Resistance

Acura Pharmaceuticals finds support from accumulated volume at $0.20.

Support: $0.20 Price: $0.21 Resistance: $0.23


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.06 between high and low, or 37.42%. For the last week the stock has had a daily average volatility of 14.34%.

Our recommended stoploss: $0.19 (-5.93%) (This stock has very high daily movements and this gives very high risk. There is a buy signal from pivot bottom found 1 days ago.)

14.34 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Buy Candidate Upgraded


Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our recommendation for this stock since last evaluation from a Strong Sell Candidate to a Buy Candidate.

Will ACUR stock price go up or down on Mon, 22 Jul 2019?

Trading With Moving Average
As an investor, you always seek to understand what other... Full Article
Pivot Points
Pivot Points refer to points of significant change. As a... Full Article
Accumulated Volume - Support and Resistance
Volume is perhaps the best indicator of all and should... Full Article
Volume - The Indicator You Really Need to Know
Many new traders getting into the world of technical analysis... Full Article
We Give Back!
In 2016 StockInvest.us donated to NGO Goodwill projects to help purchase medical... Full Article
Better Buy: Amazon vs. Facebook
Amazon's stock slipped 21% over the past six months, as... Full Article

Proudly made at